DRUG INTERACTION IN BREAST CANCER TRIPLE NEGATIVE THERAPY: DOCETAXEL AND FLUVOXAMINE. A CASE REPORT.

Fernández-García B., Fraile-Rodríguez C., Abasolo-Tamayo X., Aquerreta Gonzalez I.
Pharmacy Department. Clínica Universidad de Navarra, Pamplona.

Abstract number: 5PSQ-149
ATC code: L01 - Cytostatics

Background and importance
To alert clinicians to the potential problems of combining docetaxel (and taxanes in general) with fluvoxamine.

Aim and objectives
To report a live-conditioning interaction between docetaxel and fluvoxamine in a breast cancer patient.

Materials and Methods

- 60-year-old woman (60kg, 164cm).
- Triple negative breast ductal carcinoma (T1N0M0)

NEOADYUVANT CHEMOTHERAPY
- Epirubicin 95mg/m2 + Ciclophosphamide 600mg/m2 biweekly x 4cycles.
- Carboplatin AUC5 + Docetaxel 75mg/m2 + pegfilgrastim 6mg x4 cycles.
  (FOLLOWED BY SURGICAL INTERVENTION).

EMERGENCY ROOM:
Recurring syncopal episode and neutropenia.
It was admitted with septic shock.
Blood cultures: Pseudomonas aeruginosa. Meropenem was started.

Results

FLUVOXAMINE

DOCETAXEL

1. It was identified that the patient started taking fluvoxamine as an antidepressant the same day she started the first cycle of Docetaxel-Carboplatin.
2. The interaction between docetaxel and fluvoxamine was assimilated, and fluvoxamine was discontinued and exchanged to mirtazapine.

If PKPD analysis would have been performed, we could have proven that the AUC of docetaxel had reached toxic levels.

Conclusions and relevance

- It is mandatory to avoid utilizing SSRI that metabolizezd through CYP3A4 such as fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine in the setting of docetaxel.
- Therefore, it would be best to recommend SSRIs such as mirtazapine, citalopram and escitalopram.